Literature DB >> 15247510

Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis.

Andrew Leask1.   

Abstract

The cause of fibrotic disease is unknown. We have undertaken transcriptional profiling of dermal fibroblasts cultured from patients with the fibrotic disease scleroderma (systemic sclerosis, SSc) to identify genes overexpressed in fibrosis and have explored their contribution to the fibrotic phenotype. Connective tissue growth factor (CTGF, CCN2), a member of the CCN family of proteins, is overexpressed in SSc fibroblasts. In adult skin, CTGF is not normally expressed in dermal fibroblasts. However, CTGF is induced during the wound healing response and is constitutively overexpressed by fibroblasts present in fibrotic lesions. The overexpression of CTGF present in fibrotic lesions contributes to the phenotype of scleroderma in that CTGF promotes matrix deposition, and fibroblast adhesion and proliferation. In animal models, whereas either TGF beta or CTGF alone produce only a transient fibrotic response, CTGF and TGF beta act together to promote sustained fibrosis. Thus the constitutive overexpression of CTGF by fibroblasts present in fibrotic lesions would be expected to directly contribute to chronic, persistent fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247510     DOI: 10.2302/kjm.53.74

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  22 in total

Review 1.  Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features.

Authors:  Valérie Haydont; Marie-Catherine Vozenin-Brotons
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

2.  CCN5 Expression in mammals. II. Adult rodent tissues.

Authors:  Mark R Gray; Jennifer A Malmquist; Matthew Sullivan; Michael Blea; John J Castellot
Journal:  J Cell Commun Signal       Date:  2007-11-13       Impact factor: 5.782

Review 3.  Extracellular Matrix and Dermal Fibroblast Function in the Healing Wound.

Authors:  Lauren E Tracy; Raquel A Minasian; E J Caterson
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-03-01       Impact factor: 4.730

4.  Myofibroblast upregulators are elevated in joint capsules in posttraumatic contractures.

Authors:  Kevin A Hildebrand; Mei Zhang; David A Hart
Journal:  Clin Orthop Relat Res       Date:  2007-03       Impact factor: 4.176

5.  Connective tissue growth factor (CTGF/CCN2) in haemophilic arthropathy and arthrofibrosis: a histological analysis.

Authors:  J Jiang; N L Leong; U Khalique; T M Phan; K M Lyons; J V Luck
Journal:  Haemophilia       Date:  2016-10-05       Impact factor: 4.287

6.  TGF-β-stimulated CTGF production enhanced by collagen and associated with biogenesis of a novel 31-kDa CTGF form in human corneal fibroblasts.

Authors:  Edward G Tall; Audrey M Bernstein; Noelynn Oliver; Julia L Gray; Sandra K Masur
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-14       Impact factor: 4.799

Review 7.  A glimpse of various pathogenetic mechanisms of diabetic nephropathy.

Authors:  Yashpal S Kanwar; Lin Sun; Ping Xie; Fu-You Liu; Sheldon Chen
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

8.  Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Authors:  Olga B Garbuzenko; Vera Ivanova; Vladislav Kholodovych; David C Reimer; Kenneth R Reuhl; Edvard Yurkow; Derek Adler; Tamara Minko
Journal:  Nanomedicine       Date:  2017-04-19       Impact factor: 5.307

9.  Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway.

Authors:  Bin Zhang; Kevin K Zhou; Jian-xing Ma
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

10.  Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2009-12-03       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.